Candesartan cilexetil capsule and preparation method thereof

The preparation of candesartan medoxomil capsules by one-step fluidized bed granulation method solves the problem of candesartan medoxomil tablets turning into crystals during the tableting process, thereby improving drug stability and production efficiency, simplifying process steps and reducing costs.

CN121987583APending Publication Date: 2026-05-08珠海润都制药股份有限公司
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411569997.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-06
Publication Date
2026-05-08

AI Technical Summary

Technical Problem

Existing candesartan cilexetil tablets are prone to crystallization during tableting, which affects drug stability, and the preparation process is complex and has low production efficiency.

Method used

Candesartan medoxomil capsules were prepared using a one-step fluidized bed granulation method, which reduces the extrusion process. After one-step fluidized bed granulation, the capsules are directly filled, simplifying the process and maintaining the stability of the drug crystal form.

Benefits of technology

It improves drug stability and production efficiency, reduces industrial-scale production costs, and its dissolution profile is similar to that of the reference formulation, ensuring drug efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121987583A_ABST
    Figure CN121987583A_ABST
Patent Text Reader

Abstract

The invention provides a candesartan cilexetil capsule and a preparation method thereof, and the candesartan cilexetil capsule is characterized in that each capsule contains candesartan cilexetil, lactose, corn starch, hydroxypropyl cellulose, carboxymethyl cellulose calcium, polyethylene glycol 8000 and magnesium stearate. According to the candesartan cilexetil capsule provided by the invention, the problem of stability of candesartan cilexetil is solved, the possibility of crystal transformation of common tablets in a tabletting process is reduced, and the characteristic dissolution curve of a final product is similar to that of a reference preparation; the preparation method is simple in process route, the fluidized bed one-step granulation method enables the loss to be less, the product yield is higher, and the industrial mass production cost is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a pharmaceutical formulation of candesartan medoxomil, specifically to a candesartan medoxomil capsule with a simple process and dissolution similar to the reference formulation, and its preparation method. Background Technology

[0002] Candesartan medoxomil, developed by Takeda Pharmaceutical Company of Japan, is a prodrug of candesartan. It is completely hydrolyzed during gastrointestinal absorption to become the active candesartan, a novel angiotensin II receptor subtype AT1 antagonist that specifically targets the AT1 receptor. The original candesartan medoxomil tablets were first launched in the UK in April 1997, clinically used to treat circulatory system diseases such as hypertension, heart disease (myocardial infarction, heart failure), stroke, and nephritis. It was approved by the FDA in 1998 and marketed in the US under the brand name Atacand. In 2002, the candesartan medoxomil tablets "Blopress," manufactured by Takeda Pharmaceutical Company of Japan, were approved for import. Currently, candesartan medoxomil tablets are marketed in more than 70 countries worldwide, and improvements to candesartan medoxomil formulations are ongoing.

[0003] Patent CN101623275A discloses a capsule containing candesartan medoxomil and its preparation method. The capsule contents contain the active ingredient candesartan medoxomil, a low-melting-point oily compound, at least one disintegrant, and at least one lubricant. The capsule shell is a hydroxypropyl methylcellulose capsule shell.

[0004] In existing technologies, research on candesartan cilexetil formulations mostly focuses on improvements to the original candesartan cilexetil tablets. The few dosage form improvements are simply changes from tablet formulations to capsules. Commercially available candesartan cilexetil is generally in tablet form, manufactured through wet granulation and fluidized bed drying followed by total mixing and compression. The high-speed compression process can cause candesartan cilexetil to crystallize, affecting drug stability. This proposed candesartan cilexetil capsule formulation involves one-step fluidized bed granulation followed by capsule filling. This process is simpler, more efficient, and significantly reduces material compression, better maintaining the crystal stability of candesartan cilexetil and further ensuring the drug's stability and efficacy. Summary of the Invention

[0005] This invention provides a candesartan medoxomil capsule and its preparation method. The candesartan medoxomil capsule is characterized in that each capsule is composed of candesartan medoxomil 5-6%, lactose 70-72%, corn starch 14-15%, hydroxypropyl cellulose 4-5%, calcium carboxymethyl cellulose 1-2%, polyethylene glycol 8000 1-2%, and magnesium stearate 0.3-0.5% by weight percentage.

[0006] Furthermore, the preparation method of the candesartan cilexetil capsules includes the following steps: (a) Preparation and processing of raw materials and excipients: Weigh out the prescribed amounts of candesartan cilexetil, lactose, corn starch, polyethylene glycol 8000, hydroxypropyl cellulose, calcium carboxymethyl cellulose, and magnesium stearate for later use; (b) Preparation of adhesive: Weigh the prescribed amount of hydroxypropyl cellulose and add it to purified water to prepare a clear and transparent solution with a concentration of 5% for later use; (c) Fluidized bed one-step granulation: The candesartan ester, lactose, corn starch and polyethylene glycol 8000 weighed in step (a) are put into the fluidized bed dryer granulator. The fan frequency is turned on at 5~50Hz, the air inlet temperature is set at 40~60℃, the material temperature is controlled to ≤50℃, and then the liquid spraying is turned on to spray in the prepared binder. The liquid supply speed is 50~150rpm for one-step granulation, and finally granules with moisture content ≤3.5% are obtained for later use. (d) Granulation: The dry granules obtained in step (c) are fed into a pulverizer and granulated using a sieve with a mesh size of 0.1 mm to obtain granulated granules with a certain particle size distribution for later use. (e) Total mixing: The granules obtained in step (d) and the weighed calcium carboxymethyl cellulose are put into a clamp-type square cone mixer. The mixing speed is set to 10 rpm and the mixture is mixed for 10 min. Then the weighed magnesium stearate is added and the mixture is mixed for another 5 min to obtain the total mixed granules for later use. (f) Capsule filling: Finally, the total mixed particles obtained in step (e) are filled into gelatin empty capsules using a fully automatic hard capsule filling machine to obtain candesartan medoxomil capsules.

[0007] Currently, candesartan cilexetil is generally available in tablet form, manufactured through wet granulation and fluidized bed drying followed by total mixing and tableting. However, conventional tablets require compression, and the high-speed operation of the compression equipment can cause candesartan cilexetil to undergo crystallization, increasing the content of impurities and reducing drug stability. This solution is for candesartan cilexetil capsules, which are produced through one-step fluidized bed granulation followed by capsule filling. This process is simpler, more efficient, and significantly reduces the degree of material compression, better maintaining the crystal stability of candesartan cilexetil and further ensuring the stability and efficacy of the drug.

[0008] Compared with the prior art, the beneficial effects of the present invention are as follows: (1) The candesartan cilexetil capsules provided by the present invention solve the stability problem of candesartan cilexetil, avoid the possibility of crystallization during the compression process of ordinary tablets, and the final product has a similar characteristic dissolution curve to the reference preparation.

[0009] (2) The preparation method of candesartan medoxomil capsules provided by the present invention has a simple process route. The fluidized bed one-step granulation method simplifies the original preparation process, resulting in less loss, higher product yield, and reduced industrial production costs. Attached Figure Description

[0010] Figure 1 - Comparison of dissolution curves for pH 6.5 phosphate buffer (containing 0.35% Tween 20); Figure 2 - Comparison of dissolution curves for pH 4.5 phosphate buffer (containing 1.5% Tween 20); Figure 3 - Comparison of dissolution curves for pH 1.2 phosphate buffer (containing 2.0% Tween 20). Detailed Implementation

[0011] The present invention is further illustrated by the following examples, but these are not intended to limit the invention.

[0012] Example 1: Preparation of candesartan cilexetil capsules according to the present invention The candesartan medoxomil capsules mentioned above have the following formulation: Candesartan medoxomil 72g Hydroxypropyl cellulose 51.3g Lactose 906.3g 180g cornstarch Polyethylene glycol 8000 22.5g Carboxymethyl cellulose calcium 23.4g Magnesium stearate 4.5g The process steps are as follows: (a) Preparation and processing of raw materials and excipients: Weigh out the prescribed amounts of candesartan cilexetil, lactose, corn starch, polyethylene glycol 8000, hydroxypropyl cellulose, calcium carboxymethyl cellulose, and magnesium stearate for later use; (b) Preparation of adhesive: Weigh the prescribed amount of hydroxypropyl cellulose and add it to purified water to prepare a clear and transparent solution with a concentration of 5% for later use; (c) Fluidized bed one-step granulation: The candesartan ester, lactose, corn starch and polyethylene glycol 8000 weighed in step (a) are put into the fluidized bed dryer granulator. The fan frequency is turned on at 5~50Hz, the air inlet temperature is set at 40~60℃, the material temperature is controlled to ≤50℃, and then the liquid spraying is turned on to spray in the prepared binder. The liquid supply speed is 50~150rpm for one-step granulation, and finally granules with moisture content ≤3.5% are obtained for later use. (d) Granulation: The dry granules obtained in step (c) are fed into a pulverizer and granulated using a sieve with a mesh size of 0.1 mm to obtain granulated granules with a certain particle size distribution for later use. (e) Total mixing: The granules obtained in step (d) and the weighed calcium carboxymethyl cellulose are put into a clamp-type square cone mixer. The mixing speed is set to 10 rpm and the mixture is mixed for 10 min. Then the weighed magnesium stearate is added and the mixture is mixed for another 5 min to obtain the total mixed granules for later use. (f) Capsule filling: The total mixed particles obtained in step (e) are filled into gelatin empty capsules using a fully automatic hard capsule filling machine to obtain candesartan medoxomil capsules.

[0013] Example 2: Accelerated test study of candesartan cilexetil tablets and the self-made product of Example 1. The inner packaging products of the self-made product and the reference formulation of candesartan cilexetil tablets from Example 1 were placed in a stability test chamber, and accelerated stability testing was conducted for 6 months at a temperature of (40±2)℃ and a relative humidity of (75±5)%. Samples were taken at 0 and 6 months to detect relevant impurities, and the results are shown in Table 1 below:

[0014] Conclusion: According to the test results in Table 1, after 6 months of accelerated testing at a temperature of (40±2)℃ and a relative humidity of (75±5)%, the content of relevant impurities in the candesartan cilexetil capsules of Example 1 was significantly lower than that in the reference preparation of candesartan cilexetil tablets. While meeting the standard requirements, the stability of the candesartan cilexetil capsules was also better than that of the reference preparation.

[0015] Example 3: Dissolution determination of sample and reference formulation The candesartan medoxomil capsules and candesartan medoxomil tablets prepared in Example 1 were compared with the reference formulation in three different dissolution media, and the dissolution curves were compared as follows: The dissolution curves of the candesartan medoxomil capsules and the reference candesartan medoxomil tablets prepared in Example 1 in the dissolution medium pH 6.5 phosphate buffer (containing 0.35% Tween 20) are compared as follows. Figure 1 As shown: The dissolution curves of the candesartan medoxomil capsules and the reference candesartan medoxomil tablets prepared in Example 1 in the dissolution medium pH 4.5 phosphate buffer (containing 1.5% Tween 20) are compared as follows. Figure 2 As shown: The dissolution curves of the candesartan medoxomil capsules and the reference candesartan medoxomil tablets prepared in Example 1 in the dissolution medium pH 1.2 phosphate buffer (containing 2.0% Tween 20) are compared as follows. Figure 3 As shown.

[0016] Comparative Example: Candesartan medoxomil tablets were prepared according to the formulation described in Example 1, and the process steps are as follows: (a) Preparation and processing of raw materials and excipients: Weigh out the prescribed amounts of candesartan cilexetil, lactose, corn starch, polyethylene glycol 8000, hydroxypropyl cellulose, calcium carboxymethyl cellulose, and magnesium stearate for later use; (b) Preparation of adhesive: Weigh the prescribed amount of hydroxypropyl cellulose and add it to purified water to prepare a clear and transparent solution with a concentration of 5% for later use; (c) Fluidized bed one-step granulation: The candesartan ester, lactose, corn starch and polyethylene glycol 8000 weighed in step (a) are put into the fluidized bed dryer granulator. The fan frequency is turned on at 5~50Hz, the air inlet temperature is set at 40~60℃, the material temperature is controlled to ≤50℃, and then the liquid spraying is turned on to spray in the prepared binder. The liquid supply speed is 50~150rpm for one-step granulation, and finally granules with moisture content ≤3.5% are obtained for later use. (d) Granulation: The dry granules obtained in step (c) are fed into a pulverizer and granulated using a sieve with a mesh size of 0.1 mm to obtain granulated granules with a certain particle size distribution for later use. (e) Total mixing: The granules obtained in step (d) and the weighed calcium carboxymethyl cellulose are put into a clamp-type square cone mixer. The mixing speed is set to 10 rpm and the mixture is mixed for 10 min. Then the weighed magnesium stearate is added and the mixture is mixed for another 5 min to obtain the total mixed granules for later use. (f) Tableting: The total mixed particles obtained in step (e) are compressed into tablets using a fully automatic tablet press to obtain candesartan cilexetil tablets.

[0017] The candesartan cilexetil tablets prepared in the comparative example and the self-made product of Example 1 were then placed in a stability test chamber. The accelerated stability test conditions were set as follows: temperature (40±2)℃ and relative humidity (75±5)% for 6 months. Samples were taken at 0 and 6 months to detect relevant impurities. The results are shown in Table 2 below:

[0018] Conclusion: Based on the accelerated stability test results of the comparative self-made product and the self-made product of Example 1, it can be seen that the amount of relevant impurities detected in the comparative self-made product at 0 and 6 months is higher than that in the self-made product of Example 1. Therefore, it is easy to see that the candesartan medoxomil capsules prepared by the present invention have better stability than the candesartan medoxomil tablets prepared under the same formulation conditions. According to the test results of Example 3, in three different media, namely pH 6.5 phosphate buffer, pH 4.5 acetate buffer, and pH 1.2 hydrochloric acid solution, the characteristic dissolution curves of the candesartan medoxomil capsules prepared by the present invention are similar to those of the reference formulation of candesartan medoxomil tablets, especially when pH 1.2 hydrochloric acid solution is used as the medium.

[0019] The above embodiments are only for illustrating the technical concept and features of the present invention, and are intended to enable those skilled in the art to understand the content of the present invention and implement it accordingly. They should not be used to limit the scope of protection of the present invention.

Claims

1. A candesartan cilexetil capsule, characterized in that, Each capsule is composed of candesartan medoxomil 5-6%, lactose 70-72%, corn starch 14-15%, hydroxypropyl cellulose 4-5%, calcium carboxymethyl cellulose 1-2%, polyethylene glycol 8000 1-2%, and magnesium stearate 0.3-0.5% by weight percentage.

2. A method for preparing candesartan cilexetil capsules according to claim 1, characterized in that, Includes the following steps: (a) Preparation and processing of raw materials and excipients: Weigh out the prescribed amounts of candesartan cilexetil, lactose, corn starch, polyethylene glycol 8000, hydroxypropyl cellulose, calcium carboxymethyl cellulose, and magnesium stearate for later use; (b) Preparation of adhesive: Weigh the prescribed amount of hydroxypropyl cellulose and add it to purified water to prepare a clear and transparent solution with a concentration of 5% for later use; (c) Fluidized bed one-step granulation: The candesartan ester, lactose, corn starch and polyethylene glycol 8000 weighed in step (a) are put into the fluidized bed dryer granulator. The fan frequency is turned on at 5~50Hz, the air inlet temperature is set at 40~60℃, the material temperature is controlled to ≤50℃, and then the liquid spraying is turned on to spray in the prepared binder. The liquid supply speed is 50~150rpm for one-step granulation, and finally granules with moisture content ≤3.5% are obtained for later use. (d) Granulation: The dry granules obtained in step (c) are fed into a pulverizer and granulated using a sieve with a mesh size of 0.1 mm to obtain granulated granules with a certain particle size distribution for later use. (e) Total mixing: The granules obtained in step (d) and the prescribed amount of calcium carboxymethyl cellulose are added to a clamp-type square cone mixer. The mixing speed is set to 10 rpm and the mixture is mixed for 10 min. Then, the weighed magnesium stearate is added and the mixture is mixed for another 5 min to obtain the total mixed granules for later use. (f) Capsule filling: Finally, the total mixed particles obtained in step (e) are filled into gelatin empty capsules using a fully automatic hard capsule filling machine to obtain candesartan medoxomil capsules.

Citation Information

Patent Citations

  • Capsule containing candesartan cilexetil and preparation method thereof

    CN101623275A